NCT05100862
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Active, Not Recruiting
PHASE3Ages 18+InterventionalTreatmentBeOne Medicines
~799 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:ZanubrutinibRituximabLenalidomideObinutuzumab
At a glance
Recruiting sites
0 of 266 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Progression-free Survival As Determined By A Blinded Independent Review Committee (BIRC)
Measured over Approximately 78 months
Conditions
Where it's being run
266 sites across 89 statesBrazil22
Spain17
Italy10
Poland9
United Kingdom9
California8
France8
Victoria7
Study leadership
- Study Director · STUDY_DIRECTOR · BeOne Medicines
- Study Director · PRINCIPAL_INVESTIGATOR · BeOne Medicines
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histologically confirmed grade 1-3a FL or MZL
Previously treated with ≥ 1 line of systemic therapy including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapy
Need for systemic therapy for FL or MZL
Measurable disease by computed tomography or magnetic resonance imaging
Adequate bone marrow, liver and renal function
Exclusion
Transformation to aggressive lymphoma
Requiring ongoing need for corticosteroid treatment
Clinically significant cardiovascular disease
Prior malignancy within the past 2 years
Active fungal, bacterial, and/or viral infection that requires systemic therapy
Prior treatment with lenalidomide or drug from same class, if without response (partial or complete) or short remission duration (\< 24 months)
What this trial measures
- Progression-free Survival As Determined By A Blinded Independent Review Committee (BIRC)Approximately 78 months